I’m on the new Wegovy pill – my food cravings stopped within hours

David Clarke, a 40-year-old man from Brooklyn, New York City, has reported a dramatic shift in his eating habits after starting the new Wegovy pill. Having struggled with weight management since childhood, Clarke had previously managed to lose weight in his early thirties through a strict diet and participation in a rugby team. However, as he entered his mid-thirties, lifestyle changes led to a gradual increase in weight, gaining approximately 22 kilograms over five years. His recent health checkup revealed elevated cholesterol levels, prompting him to seek a solution to regain control of his weight. Clarke's interest in the Wegovy pill was sparked by an advertisement for the telehealth company Hims. His mother, who suffers from type 2 diabetes, has been using the injectable weight loss medication Mounjaro with notable success. Despite this, Clarke hesitated to consider injections due to a long-standing fear of needles, a common issue affecting roughly one in ten people in the UK. The availability of a daily pill formulation of Wegovy, originally an injectable drug, presented a more appealing alternative for someone like Clarke, who finds the prospect of regular injections uncomfortable. Clarke obtained the Wegovy pill through Hims around six weeks ago. Shortly after beginning the treatment, he observed a marked decrease in his usual food cravings. Specifically, he noted a significant reduction in his desire for sweet foods such as desserts, cakes, ice cream, and cookies. Within hours of his initial dose, he described a noticeable quieting of these cravings. After transitioning to a higher dosage, he reported that the effect had become almost complete. This rapid suppression of food-related thoughts contrasts sharply with his previous experiences, during which he often found himself preoccupied with the idea of indulging in his favorite treats. While the weight loss has been steady rather than dramatic, Clarke has shed just over 2.5 kilograms in six weeks, the near-immediate reduction in food cravings has made the Wegovy pill one of the most anticipated drug launches in recent memory. The development of a pill form of Wegovy marks a significant milestone in the evolution of weight loss treatments, particularly given the growing demand for non-invasive options. Over the past decade, GLP-1 receptor agonists, medications that mimic the action of natural gut hormones that suppress appetite, have gained popularity among healthcare professionals and patients alike. These injectable drugs have shown effectiveness in helping individuals manage their weight. However, the challenge of administering injections has spurred research into developing oral alternatives. The Wegovy pill represents the first successful attempt at creating a tablet version of a GLP-1 drug, paving the way for future innovations in this field. Eli Lilly, the pharmaceutical company behind Wegovy, has also developed another GLP-1 pill named orforglipron, which could be available in the UK by the end of 2026. Similarly, AstraZeneca is conducting clinical trials on its oral GLP-1 drug, elecoglipron. Both companies are contributing to the expanding landscape of weight management solutions, driven by the increasing preference for convenient, non-invasive methods. The transition from injectable to oral formulations brings both advantages and challenges. While pills offer greater ease of use and storage, they also present unique side effects. Clinical trials have indicated that while the Wegovy pill leads to similar weight loss outcomes compared to injections, it causes more frequent instances of nausea. Conversely, users report experiencing fewer gastrointestinal issues such as diarrhea or constipation, which are commonly associated with injectable forms of GLP-1 drugs.